Key result
Combination therapy with a calcium channel blocker and angiotensin receptor blocker may improve long-term blood pressure control in patients remaining 20 mm Hg higher than their goal.
Why the study?
Does CCB/ARB combination therapy improve long-term blood pressure control and adherence in patients with hypertension?
Does CCB/ARB combination therapy improve long-term blood pressure control and adherence in patients with hypertension?
CCB/ARB combination therapy, particularly in fixed-dose regimens, offers a compelling strategy to improve long-term blood pressure control and patient adherence.
Long-term BP control challenges in one-third of high-risk patients persist; leaves open optimal primary care strategies for sustained hypertension management.
There are unique problems associated with the long-term control of blood pressure (BP) in patients with hypertension. Many of these problems warrant specific discussion for the primary care physician. Up to one-third of high-risk patients are estimated to have uncontrolled hypertension. Although long-term control is essential to avoid complications of cardiovascular disease, such as myocardial infarction, stroke, heart failure, and kidney disease, it can become troublesome because of challenges with patient compliance and adherence to medication regimens. This may be due to low tolerability profiles, complicated regimens, or prohibitive costs. Trials have shown that a combination approach may reduce side effects with complementary therapies such as a calcium channel blocker (CCB)/angiotensin receptor blocker (ARB) combination. Combination therapy can be used in any patient group not responsive to monotherapy, or who remain 20 mm Hg higher than their BP goal. This method may achieve the goal of reaching target BP sooner as a first-line approach and, in a fixed-dose combination, may be a more economic choice as well as a simpler regimen for the patient. Together with supportive measures, CCB/ARB combinations are a compelling alternative for the long-term treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
Joel M. Neutel (2011) conducted a review in Hypertension. Calcium channel blocker (CCB)/angiotensin receptor blocker (ARB) combination vs. Monotherapy was evaluated. Combination therapy with a calcium channel blocker and angiotensin receptor blocker may improve long-term blood pressure control in patients remaining 20 mm Hg higher than their goal.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: